Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Ooft SN"" wg kryterium: Autor


Wyświetlanie 1-4 z 4
Tytuł :
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
Autorzy :
Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Schipper L; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
McLean CM; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Prevoo W; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Velden D; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center AMC, Amsterdam, The Netherlands.
van Leerdam M; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Boot H; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Grootscholten C; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
Cuppen E; Oncode Institute, Utrecht, The Netherlands; Division of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100103. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
Autorzy :
Fernandes Neto JM; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Nadal E; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
Bosdriesz E; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Computer Science, Faculty of Science, Vrije Universiteit, Amsterdam, The Netherlands.
Ooft SN; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
Farre L; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.; Institute Gonçalo Moniz, Fundaçao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brasil.
McLean C; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
Klarenbeek S; Experimental Animal Pathology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
Jurgens A; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Hagen H; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Wang L; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Autonomous University of Barcelona (UAB), Barcelona, Spain.
Martinez-Marti A; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Autonomous University of Barcelona (UAB), Barcelona, Spain.
Vidal A; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
Voest E; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
Wessels LFA; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
van Tellingen O; Division of Clinical Pharmacology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
Villanueva A; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.; Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain.
Bernards R; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Jun 22; Vol. 11 (1), pp. 3157. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
ErbB Receptors/*genetics
Protein Kinase Inhibitors/*pharmacology
Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/toxicity ; Carcinoma, Non-Small-Cell Lung/genetics ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Resistance, Neoplasm/genetics ; Humans ; Lung Neoplasms/drug therapy ; MAP Kinase Signaling System/drug effects ; Mice ; Models, Animal ; Mutation ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/toxicity ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Autorzy :
Ooft SN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
McLean CM; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Schipper L; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Hoes L; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Vis DJ; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Prevoo W; Department of Radiology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van der Velden D; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Klein M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Boot H; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van Leerdam M; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, 6525 GA Nijmegen, Netherlands.
Beerepoot LV; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, 5042 AD Tilburg, Netherlands.
Wessels L; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, 2628 CD Delft, Netherlands.
Cuppen E; Oncode Institute, 3521 AL Utrecht, Netherlands.; Division Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, 3584 CX Utrecht, Netherlands.; Hartwig Medical Foundation, 1098 XH Amsterdam, Netherlands.
Clevers H; Oncode Institute, 3521 AL Utrecht, Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Centre Utrecht, 3584 CT Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands. .; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Pokaż więcej
Źródło :
Science translational medicine [Sci Transl Med] 2019 Oct 09; Vol. 11 (513).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Colorectal Neoplasms/*metabolism
Colorectal Neoplasms/*pathology
Organoids/*cytology
Antineoplastic Agents/therapeutic use ; Capecitabine/therapeutic use ; Colorectal Neoplasms/drug therapy ; Female ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Oxaliplatin/therapeutic use ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.
Autorzy :
Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Foundation Hubrecht Organoid Technology (HUB), Utrecht, Utrecht 3584CM, the Netherlands; Cancer Genomics.nl, Utrecht, Utrecht 3584 CG, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Cell chemical biology [Cell Chem Biol] 2017 Sep 21; Vol. 24 (9), pp. 1092-1100. Date of Electronic Publication: 2017 Jul 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Discovery*
Models, Biological*
Neoplasms/*therapy
Animals ; Antineoplastic Agents/therapeutic use ; CRISPR-Cas Systems ; Cell Culture Techniques ; Cystic Fibrosis/therapy ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Humans ; Neoplasms/drug therapy ; Neoplasms/pathology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
    Wyświetlanie 1-4 z 4

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies